FDA grants fast track designation for novel Duchenne muscular dystrophy gene therapy
Regenxbio Inc. announced that the FDA has granted fast track designation for RGX-202, a one-time gene therapy for treatment of Duchenne muscular dystrophy.According to a release from the company, the FDA previously granted orphan drug designation and rare pediatric disease designation for RGX-202, which is designed to support delivery and expression of genes in heart and skeletal muscle using the